New hope for cancer patients: drug may stop dangerous weight loss before surgery

NCT ID NCT07391826

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a drug called megestrol acetate can help prevent weight loss in people with stage III stomach cancer who are about to have surgery. About 48 participants will receive either standard treatment (chemoimmunotherapy) or standard treatment plus megestrol acetate. The goal is to see if the drug helps maintain weight and appetite during treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE III GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • First Affiliated Hospital of Nanjing Medical Unviersity

    Nanjing, Jiangsu, 210000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.